Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,667 Million (Small Cap)
17.00
NA
2.10%
-0.76
5.62%
1.00
Revenue and Profits:
Net Sales:
57 Million
(Quarterly Results - Sep 2025)
Net Profit:
17 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.02%
0%
22.02%
6 Months
21.75%
0%
21.75%
1 Year
38.02%
0%
38.02%
2 Years
58.03%
0%
58.03%
3 Years
-15.03%
0%
-15.03%
4 Years
7.87%
0%
7.87%
5 Years
-11.46%
0%
-11.46%
Beijing Succeeder Technology, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.94%
EBIT Growth (5y)
5.08%
EBIT to Interest (avg)
90.16
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.17
Tax Ratio
13.21%
Dividend Payout Ratio
30.84%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
46.66%
ROE (avg)
6.79%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
1.00
EV to EBIT
4.49
EV to EBITDA
3.92
EV to Capital Employed
1.00
EV to Sales
1.39
PEG Ratio
NA
Dividend Yield
2.12%
ROCE (Latest)
22.40%
ROE (Latest)
5.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
56.70
67.50
-16.00%
Operating Profit (PBDIT) excl Other Income
13.60
20.20
-32.67%
Interest
0.00
0.00
Exceptional Items
-0.40
-0.10
-300.00%
Consolidate Net Profit
16.50
20.90
-21.05%
Operating Profit Margin (Excl OI)
239.10%
252.40%
-1.33%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is -16.00% vs 7.48% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -21.05% vs -24.28% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
301.20
272.70
10.45%
Operating Profit (PBDIT) excl Other Income
113.20
105.20
7.60%
Interest
0.10
0.10
Exceptional Items
0.20
0.00
Consolidate Net Profit
112.90
116.90
-3.42%
Operating Profit Margin (Excl OI)
336.60%
367.70%
-3.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 10.45% vs 20.29% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -3.42% vs 12.30% in Dec 2023
About Beijing Succeeder Technology, Inc. 
Beijing Succeeder Technology, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






